ACAD
Price
$16.50
Change
-$4.73 (-22.28%)
Updated
Nov 9 closing price
Capitalization
3.66B
111 days until earnings call
Intraday BUY SELL Signals
ZURA
Price
$1.24
Change
-$2.85 (-69.68%)
Updated
Nov 9 closing price
Capitalization
391.94M
141 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

ACAD vs ZURA

ACAD vs ZURA Comparison Chart in %
View a ticker or compare two or three
VS
ACAD vs. ZURA commentary
Nov 10, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ACAD is a StrongBuy and ZURA is a Hold.

Interact to see
Advertisement
SUMMARIES
A.I.Advisor
a Summary for ACAD with price predictions
Nov 09, 2026

ACAD in +4.88% Uptrend, advancing for three consecutive days on November 04, 2026

Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where ACAD advanced for three days, in 189 of 253 cases, the price rose further within the following month. The odds of a continued upward trend are 75%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The RSI Indicator entered the oversold zone -- be on the watch for ACAD's price rising or consolidating in the future. That's also the time to consider buying the stock or exploring call options.

The Moving Average Convergence Divergence (MACD) for ACAD just turned positive on October 15, 2026. Looking at past instances where ACAD's MACD turned positive, the stock continued to rise in 33 of 46 cases over the following month. The odds of a continued upward trend are 72%.

ACAD may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 39 of 61 cases where ACAD's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 64%.

The Momentum Indicator moved below the 0 level on November 09, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on ACAD as a result. In 65 of 96 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 68%.

The 50-day moving average for ACAD moved below the 200-day moving average on November 02, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where ACAD declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 70%.

The Aroon Indicator for ACAD entered a downward trend on October 22, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron SMR rating for this company is 28 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Price Growth Rating for this company is 58 (best 1 - 100 worst), indicating steady price growth. ACAD’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of 80 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.800) is normal, around the industry mean (3.498). P/E Ratio (9.394) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (4.168) is also within normal values, averaging (440.869).

The Tickeron PE Growth Rating for this company is 82 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Seasonality Score of 85 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ACAD’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.

A.I.Advisor
a Summary for ZURA with price predictions
Nov 09, 2026

ZURA in -18.64% downward trend, declining for three consecutive days on October 23, 2026

Moving lower for three straight days is viewed as a bearish sign. Keep an eye on this stock for future declines. Considering data from situations where ZURA declined for three days, in 195 of 238 cases, the price declined further within the following month. The odds of a continued downward trend are 82%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on November 09, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on ZURA as a result. In 52 of 80 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 65%.

The Moving Average Convergence Divergence Histogram (MACD) for ZURA turned negative on November 09, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 61 similar instances when the indicator turned negative. In 41 of the 61 cases the stock turned lower in the days that followed. This puts the odds of success at 67%.

The Aroon Indicator for ZURA entered a downward trend on October 22, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Bullish Trend Analysis

The RSI Indicator entered the oversold zone -- be on the watch for ZURA's price rising or consolidating in the future. That's also the time to consider buying the stock or exploring call options.

The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 44 of 62 cases where ZURA's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 71%.

Following a +2.03% 3-day Advance, the price is estimated to grow further. Considering data from situations where ZURA advanced for three days, in 153 of 188 cases, the price rose further within the following month. The odds of a continued upward trend are 81%.

ZURA may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 21 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating of 30 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.989) is normal, around the industry mean (3.498). P/E Ratio (-3.652) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (440.869).

The Tickeron Price Growth Rating for this company is 61 (best 1 - 100 worst), indicating steady price growth. ZURA’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ZURA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.

FUNDAMENTALS RATINGS
ACAD: Fundamental Ratings
ACAD
OUTLOOK RATING
1..100
11
VALUATION
overvalued / fair valued / undervalued
1..100
80
Overvalued
PROFIT vs RISK RATING
1..100
100
SMR RATING
1..100
28
PRICE GROWTH RATING
1..100
58
P/E GROWTH RATING
1..100
82
SEASONALITY SCORE
1..100
85

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
ACADZURA
RSI
ODDS (%)
Bullish Trend 1 day ago
64%
Bullish Trend 1 day ago
88%
Stochastic
ODDS (%)
Bearish Trend 1 day ago
64%
Bullish Trend 1 day ago
71%
Momentum
ODDS (%)
Bearish Trend 1 day ago
68%
Bearish Trend 1 day ago
65%
MACD
ODDS (%)
Bullish Trend 1 day ago
72%
Bearish Trend 1 day ago
67%
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
68%
Bearish Trend 1 day ago
72%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
71%
Bearish Trend 1 day ago
75%
Advances
ODDS (%)
Bullish Trend 6 days ago
75%
Bullish Trend 6 days ago
81%
Declines
ODDS (%)
Bearish Trend 1 day ago
70%
Bearish Trend 18 days ago
82%
BollingerBands
ODDS (%)
Bullish Trend 1 day ago
70%
Bullish Trend 1 day ago
82%
Aroon
ODDS (%)
Bearish Trend 1 day ago
69%
Bearish Trend 1 day ago
76%
COMPARISON
Comparison
Nov 10, 2026
Stock price -- (ACAD: $16.50 vs. ZURA: $4.09)
Brand notoriety: ACAD and ZURA are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ACAD: 621% vs. ZURA: 94%
Market capitalization -- ACAD: $3.66B vs. ZURA: $391.94M
ACAD [@Biotechnology] is valued at $3.66B. ZURA’s [@Biotechnology] market capitalization is $391.94M. The market cap for tickers in the [@Biotechnology] industry ranges from $58 to $138.67B. The average market capitalization across the [@Biotechnology] industry is $2.23B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ACAD’s FA Score shows that 1 FA rating(s) are green while ZURA’s FA Score has 2 green FA rating(s).

  • ACAD’s FA Score: 1 green, 4 red.
  • ZURA’s FA Score: 2 green, 3 red.
According to our system of comparison, ZURA is a better buy in the long-term than ACAD.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ACAD’s TA Score shows that 4 TA indicator(s) are bullish while ZURA’s TA Score has 6 bullish TA indicator(s).

  • ACAD’s TA Score: 4 bullish, 5 bearish.
  • ZURA’s TA Score: 6 bullish, 3 bearish.
According to our system of comparison, ZURA is a better buy in the short-term than ACAD.

Price Growth

ACAD (@Biotechnology) experienced а -19.39% price change this week, while ZURA (@Biotechnology) price change was +1.24% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +2.23%. For the same industry, the average monthly price growth was -8.97%, and the average quarterly price growth was +85.13%.

Reported Earning Dates

ACAD is expected to report earnings on Mar 01, 2027.

ZURA is expected to report earnings on Mar 31, 2027.

Industries' Descriptions

@Biotechnology (+2.23% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

View a ticker or compare two or three
Interact to see
Advertisement

ZURA and

Correlation & Price change

A.I.dvisor indicates that over the last year, ZURA has been loosely correlated with ACAD. These tickers have moved in lockstep 58% of the time. This A.I.-generated data suggests there is some statistical probability that if ZURA jumps, then ACAD could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ZURA
1D Price
Change %
ZURA100%
-69.68%
ACAD - ZURA
58%
Loosely correlated
-22.28%
IONS - ZURA
51%
Loosely correlated
-21.36%
VIR - ZURA
44%
Loosely correlated
+11.75%
RCUS - ZURA
42%
Loosely correlated
+3.67%
FDMT - ZURA
40%
Loosely correlated
+1.88%
More
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
CRYPTO / NAMEPrice $Chg $Chg %
DASH.X47.0624401.911144
+4.23%
Dash cryptocurrency
TFUEL.X0.0075420.000239
+3.27%
Theta Fuel cryptocurrency
CHESS.X0.0000740.000001
+0.88%
Tranchess cryptocurrency
POLS.X0.0502640.000390
+0.78%
Polkastarter cryptocurrency
BLUR.X0.006594-0.000099
-1.48%
Blur cryptocurrency